VEIEX
Price
$37.24
Change
-$0.17 (-0.45%)
Updated
Jul 2 closing price
Net Assets
162.82B
VREMX
Price
$7.78
Change
+$0.03 (+0.39%)
Updated
Jul 2 closing price
Net Assets
426.01M
Interact to see
Advertisement

VEIEX vs VREMX

VEIEX vs VREMX Comparison Chart in %
View a ticker or compare two or three
VS
VEIEX vs. VREMX commentary
Jul 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is VEIEX is a Hold and VREMX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VEIEX has more cash in the bank: 163B vs. VREMX (426M). VREMX pays higher dividends than VEIEX: VREMX (2.61) vs VEIEX (2.16). VEIEX was incepted earlier than VREMX: VEIEX (32 years) vs VREMX (12 years). VREMX (1.23) is less costly to investors than VEIEX (0.29). VREMX is a more actively managed with annual turnover of: 23.00 vs. VEIEX (6.00). VEIEX has a lower initial minimum investment than VREMX: VEIEX (0) vs VREMX (2500000). VEIEX annual gain was more profitable for investors over the last year : 20.13 vs. VREMX (-5.31). VEIEX return over 5 years is better than : 20.74 vs. VREMX (-40.96).
VEIEXVREMXVEIEX / VREMX
Total Expense Ratio0.290.9830%
Annual Report Gross Expense Ratio0.291.2324%
Fund Existence32 years12 years-
Gain YTD9.573-9.112-105%
Front LoadN/AN/A-
Min. Initial Investment02500000-
Min. Initial Investment IRAN/AN/A-
Net Assets163B426M38,263%
Annual Yield % from dividends2.162.6183%
Returns for 1 year20.13-5.31-379%
Returns for 3 years52.16-0.46-11,319%
Returns for 5 years20.74-40.96-51%
Returns for 10 years95.51-13.56-704%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LBDRX23.570.31
+1.33%
BrandywineGLOBAL Div US Large Value R
EPLKX24.490.17
+0.70%
NYLI Epoch U.S. Equity Yield Class C
EMGRX12.62-0.08
-0.63%
Nuveen Small Cap Select A
MEGBX113.07-0.83
-0.73%
MFS Growth B
FSMRX32.81-0.46
-1.38%
Franklin Small-Mid Cap Growth R